Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study - Fassnacht, M; Berruti, A; Baudin, E (Lancet Oncol, 2015)
et al.